国产创新药突围乳腺癌治疗,恒瑞医药、百利天恒等多点开花

制药网
Jan 14

乳腺癌已成为威胁我国女性生命健康的主要恶性肿瘤之一,有数据显示,2022年我国乳腺癌新发病例已超过35万例,这一庞大的患者群体面临着迫切的治疗需求。在这一严峻背景下,国内药企积极加码乳腺癌治疗领域布局,多款自主研发的创新药物接连取得关键性进展,为患者带来了新的生存希望。如恒瑞医药的瑞康曲妥珠单抗针对HER2+乳腺癌二线治疗的新适应症上市申请已获国家药监局受理,并被纳入优先审评程序;同时,公司还...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10